12V Stock Chart & Stats
€27.60
-€0.40(-0.97%)
At close: 4:00 PM EST
€27.60
-€0.40(-0.97%)
Day’s Range― - ―
52-Week Range€19.50 - €52.72
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€4.14B
Enterprise Value€3.87B
Total Cash (Recent Filing)€439.06M
Total Debt (Recent Filing)€39.33M
Price to Earnings (P/E)51.3
Beta0.59
Next Earnings
Jul 30, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding79,792,650
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€48.51Price Target Upside75.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)1.6
Revenue Forecast (FY)€512.86M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base provide durable financial flexibility. This reduces refinancing and solvency risk, allows the company to fund R&D, commercialization and potential M&A from internal resources, and cushions the business against cyclical shortfalls over the next 2–6 months.
Improving Cash Generation & ProfitabilitySustained positive operating cash flow and expanding adjusted EBITDA margins indicate durable earnings quality and strong cash conversion. This supports continued investment in launches and commercialization while reducing dependence on external capital, strengthening the company’s multi-month runway.
Commercial Momentum And Evidence-rich PipelineConsistent Decipher growth plus a growing clinical evidence base and near-term product catalysts (Prosigna LDT, TruMRD) enhance long-term commercial runway. Robust trial programs and large research assets support clinician adoption and durable market share in oncology diagnostics.
Bears Say
Binary Clinical Readouts RiskKey product commercialization and labeling depend on binary Phase 3 and metastatic trial outcomes. Negative or delayed readouts could materially postpone guideline inclusion, limit label claims and slow clinician uptake, impairing projected revenue contributions over the coming quarters.
Revenue Growth DecelerationA slowdown from prior multi-year expansion to mid-single-digit TTM growth reduces the firm’s ability to leverage fixed costs and compresses the margin upside available from volume. Sustained deceleration forces greater dependence on new-product launches and reimbursement wins to reaccelerate growth.
Guideline & Reimbursement Timing UncertaintyEven with positive data, delayed guideline updates and slow payer coverage can materially defer revenue realization. Reimbursement timing is structural for durable test utilization; uncertainty here can blunt adoption curves and prolong the interval before new tests meaningfully contribute to recurring revenue.
Veracyte News
12V FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was €19.50 and its highest was €52.72 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is €4.14B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on May 05, 2026. The company reported €0.455 earnings per share for the quarter, beating the consensus estimate of €0.293 by €0.163.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.38.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 79,792,650 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of €0.455 in its last earnings report, beating expectations of €0.293. Following the earnings report the stock price went up 14.8%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in DE:12V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€48.51 (75.75% Upside)
€48.51 (75.75% Upside)
Blogger Sentiment
Bullish
DE:12V Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth €955.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.98%
12-Months-Change
Fundamentals
Return on Equity
6.86%
Trailing 12-Months
Asset Growth
9.20%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
12V Company Deck
12V Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all DE:12V earnings summaries12V Stock 12 Month Forecast
Average Price Target
€48.51
▲(75.75% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Options Prices
Currently, No data available
---